FindTrial
Sign In

LY3484356

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Advanced Breast CancerBreast CancerBreast NeoplasmsEndometrial CancerHealthyMetastatic Breast Cancer

Phase 1

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Active, not recruitingNCT04188548
Eli Lilly and CompanyAdvanced Breast Cancer, Breast Cancer, Endometrial Cancer +1
Start: 2019-12-10End: 2027-12-31Target: 500Updated: 2025-06-04
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
CompletedNCT04647487
Eli Lilly and CompanyBreast Cancer
Start: 2021-04-21End: 2022-11-11Updated: 2025-11-12
A Study of LY3484356 in Healthy Female Participants
CompletedNCT04840888
Eli Lilly and CompanyHealthy
Start: 2021-04-26End: 2022-04-12Updated: 2025-12-11
A Study of [¹⁴C]-LY3484356 in Healthy Female Participants
CompletedNCT04991766
Eli Lilly and CompanyHealthy
Start: 2021-08-13End: 2022-04-02Updated: 2025-12-05
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
Active, not recruitingNCT05509790
Eli Lilly and CompanyBreast Neoplasms
Start: 2022-10-09End: 2026-12-01Updated: 2026-04-13

Related Papers

Phase 1 Study Evaluating the Effect of Food and Omeprazole-Induced Gastric pH Change on the Pharmacokinetics and Safety of Imlunestrant in Healthy Females.
2025-11-21
Abstract CT027: Imlunestrant, a novel orally bioavailable selective estrogen receptor degrader (SERD) in Chinese patients with ER positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (mBC): Results from a phase 1 study
Cancer Research2025-04-251 citations
Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of <scp>CYP3A4</scp> Induction
Clinical Pharmacology & Therapeutics2024-06-121 citations
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.
Journal of Clinical Oncology2024-06-012 citations
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.
Journal of Clinical Oncology2024-06-01
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
BMC Cancer2024-05-246 citations
Abstract PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
Cancer Research2024-05-022 citations
51P ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study
ESMO Open2024-05-01
Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study
Cancer Research2023-03-0111 citations
Abstract P6-10-06: A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: Results from the EMBER-2 study
Cancer Research2023-03-015 citations
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
Journal of Clinical Oncology2022-06-0138 citations
Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)
Cancer Research2021-07-0128 citations
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.
Journal of Clinical Oncology2021-05-2036 citations
Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer
Cancer Research2021-02-159 citations